Ying Yuan

The University of Texas MD Anderson Cancer Center

Also affiliated with Capital Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking University, Beijing Jishuitan Hospital, Jinyintan Hospital, Xiangyang Central Hospital, National Cancer Institute, Second Affiliated Hospital of Zhejiang University, Chongqing Medical and Pharmaceutical College, Ocean University of China, Chongqing Jiaotong University, Zhejiang University

MathematicsDecision SciencesEconomics, Econometrics and FinanceBiochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 3%percentile

1.0Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Analysis of INSPPIRE‐2 Cohort

Journal of Pediatric Gastroenterology and Nutrition(2022)10.1097/mpg.0000000000003590

Top 27%

0.751DataRank

Top 27%39 citations

Gretchen A. Cress, Fuchenchu Wang, Maisam Abu‐El‐Haija, Kate Ellery, Douglas S. Fishman +20 more

Papers

Driven by 64 papers — median percentile 57. Top paper: “Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer”.

Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer

American Journal of Obstetrics and Gynecology(2020)10.1016/j.ajog.2020.08.032

N/A

4.0DataRank · unranked

125 citations

Bryan Fellman, Charlotte C. Sun, Russell R. Broaddus, Misty Woodall, Navdeep Pal +14 more

Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification

Journal of Clinical Oncology(2022)10.1200/jco.22.00830

N/A

2.2DataRank · unranked

97 citations

Shuyang Yao, Yuan Yuan, Rebecca A. Previs, Anthony Elias, Richard D. Carvajal +15 more

Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-006822

N/A

1.3DataRank · unranked

52 citations

Anne Knisely, David Vining, Scott Kopetz, Michael J. Overman, Milind Javle +16 more

Hippocampus and cognitive domain deficits in treatment-resistant schizophrenia: A comparison with matched treatment-responsive patients and healthy controls✰,✰✰,★,★★

Psychiatry Research Neuroimaging(2020)10.1016/j.pscychresns.2020.111043

N/A

1.0DataRank · unranked

30 citations

Yu Zhu, Fengmei Fan, Song Chen, Yuan Hong, Yimin Cui +14 more

Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial

The Lancet Oncology(2023)10.1016/s1470-2045(23)00478-3

N/A

0.960DataRank · unranked

34 citations

Jessica M. Frakes, Todd A. Aguilera, Manisha Palta, Brian G. Czito, Manoop S. Bhutani +26 more

Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

Cancer Research Communications(2023)10.1158/2767-9764.crc-22-0260

N/A

0.943DataRank · unranked

37 citations

Niamh Coleman, Sarina A. Piha‐Paul, Apostolia M. Tsimberidou, Filip Jankú, Jordi Rodón +13 more

Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy in High-Grade Epithelial Ovarian Cancer

JAMA Network Open(2024)10.1001/jamanetworkopen.2024.46325

N/A

0.891DataRank · unranked

23 citations

Alexander Melamed, René Pareja, Taymaa May, Abdulrahman Sinno, Leah McNally +9 more

PPP2R1A mutations portend improved survival after cancer immunotherapy

Nature(2025)10.1038/s41586-025-09203-8

N/A

0.793DataRank · unranked

30 citations

Anne Knisely, Mitsutake Yano, Minghao Dang, Emily Hinchcliff, Sanghoon Lee +36 more

Analysis of INSPPIRE‐2 Cohort

Journal of Pediatric Gastroenterology and Nutrition(2022)10.1097/mpg.0000000000003590

Top 27%

0.751DataRank

Top 27%39 citations

Gretchen A. Cress, Fuchenchu Wang, Maisam Abu‐El‐Haija, Kate Ellery, Douglas S. Fishman +20 more

Phase I–II clinical trial design: a state-of-the-art paradigm for dose finding

Annals of Oncology(2018)10.1093/annonc/mdx795

N/A

0.677DataRank · unranked

90 citations

P.F. Thall, K.H. Lu, M.R. Gilbert, Ying Yuan, F. Yan

EFFORT: EFFicacy Of adavosertib in parp ResisTance: A randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5505

N/A

0.665DataRank · unranked

83 citations

Robert L. Coleman, Bryan Fellman, Ying Yuan, Anil K. Sood, Pamela T. Soliman +15 more

Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer

Cancers(2021)10.3390/cancers13050946

N/A

0.621DataRank · unranked

62 citations

Amir A. Jazaeri, Bryan Fellman, Molly S. Daniels, Suzanna Penn, Cara Solimeno +7 more

A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma

Neuro-Oncology(2020)10.1093/neuonc/noaa240

N/A

0.621DataRank · unranked

62 citations

Ying Yuan, Jimin Wu, Tito R. Mendoza, Elizabeth Vera, Antonio Omuro +9 more

Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4730

N/A

0.617DataRank · unranked

60 citations

Ying Yuan, Debra A. Long Priel, Danielle Fink, Cody J. Peer, Tristan M. Sissung +30 more

Proton Image-guided Radiation Assignment for Therapeutic Escalation via Selection of locally advanced head and neck cancer patients [PIRATES]: A Phase I safety and feasibility trial of MRI-guided adaptive particle radiotherapy

Clinical and Translational Radiation Oncology(2021)10.1016/j.ctro.2021.11.003

N/A

0.531DataRank · unranked

8 citations

Steven J. Frank, Ying Yuan, Brandon Gunn, Amy C. Moreno, Abdallah Mohamed +11 more

Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer

BMJ Oncology(2024)10.1136/bmjonc-2023-000133

N/A

0.473DataRank · unranked

13 citations

Genevieve Hartley, Coline Couillault, Ying Yuan, Heather Lin, Courtney Nicholas +18 more

Pancreatic Enzyme Use Reduces Pancreatitis Frequency in Children With Acute Recurrent or Chronic Pancreatitis: A Report From INSPPIRE

The American Journal of Gastroenterology(2024)10.14309/ajg.0000000000002772

N/A

0.470DataRank · unranked

22 citations

Kenneth Ng, Fuchenchu Wang, Maisam Abu‐El‐Haija, Ankur Chugh, Gretchen A. Cress +25 more

A Phase I–II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes

Bayesian Analysis(2020)10.1214/20-ba1205

N/A

0.434DataRank · unranked

17 citations

Peter F. Thall, Ying Yuan, Ruitao Lin

Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2819

N/A

0.385DataRank · unranked

12 citations

Yingao Zhang, Heather Lin, Oriol Mirallas, Pablo Álvarez Ballesteros, Mirella Nardo +19 more

Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial

Med(2024)10.1016/j.medj.2024.07.022

N/A

0.299DataRank · unranked

4 citations

Minghao Dang, Sanghoon Lee, Bryan Fellman, Shannon N. Westin, Anil K. Sood +19 more

Evaluation of Deviation From Planned Cohort Size and Operating Characteristics of Phase 1 Trials

JAMA Network Open(2021)10.1001/jamanetworkopen.2020.37563

N/A

0.292DataRank · unranked

6 citations

Suyu Liu, Timothy A. Yap, Ying Yuan, Minjeong Park

Safety, Tolerability, and Dose-Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis: Protocol for a Phase 1 Clinical Trial to Determine Safety and Identify Side Effects

JMIR Research Protocols(2024)10.2196/50513

N/A

0.291DataRank · unranked

4 citations

Jeffrey J. Easler, Ying Yuan, Dhiraj Yadav, Darwin L. Conwell, Santhi Swaroop Vege +5 more

Clinical and genetic markers of vascular toxicity in glioblastoma patients: Insights from NRG Oncology RTOG-0825

Neuro-Oncology(2024)10.1093/neuonc/noae234

Top 59%

0.261DataRank

Top 59%4 citations

Mark R. Gilbert, Minesh P. Mehta, Ang Li, Renke Zhou, Melissa L. Bondy +18 more

A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison

Biometrics(2024)10.1093/biomtc/ujad022

N/A

0.241DataRank · unranked

4 citations

Peter F. Thall, Ying Yuan, Yong Zang

Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3531

N/A

0.208DataRank · unranked

3 citations

Filip Jankú, Ying Yuan, Leylah Drusbosky, Alice P. Chen, Xiaofeng Zheng +15 more

Phase II trial evaluating nivolumab in patients with recurrent IDH-mutant gliomas with and without hypermutation phenotype.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e14043

N/A

0.165DataRank · unranked

2 citations

Ying Yuan, Kelly Mentges, Jennifer Reyes, Tito R. Mendoza, Terri S. Armstrong +13 more

EON: Phase II trial of etigilimab (MPH313) in combination with nivolumab in patients with recurrent platinum-resistant clear cell ovarian cancer.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.5573

N/A

0.104DataRank · unranked

1 citations

Emily Hinchcliff, Shuqi Wang, Amir A. Jazaeri, Anil K. Sood, Bryan Fellman +14 more

Circulating tumour cell and cell-free DNA kinetics during radiotherapy in patients with intact head and neck squamous cell carcinoma

medRxiv(2020)10.1101/2020.10.13.20211516

N/A

0.104DataRank · unranked

1 citations

Carolyn Hall, Salyna Meas, Vanessa N. Sarli, Houda Bahig, Carlos Cárdenas +19 more

A generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints

Biometrical Journal(2024)10.1002/bimj.202300122

N/A

0.104DataRank · unranked

1 citations

Ying Yuan, Zhangsheng Yu, Ruitao Lin, Xiaohan Chi

First-in-human dose escalation and food effect study of oral ONC206 in adults with recurrent primary CNS neoplasms.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps2072

N/A

0DataRank · unranked

2 citations

Jinkyu Jung, Eric Burton, Heather Leeper, Jing Wu, Kareem A. Zaghloul +12 more

Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum‐resistant ovarian cancer

Cancer(2023)10.1002/cncr.35126

N/A

0DataRank · unranked

18 citations

Anne Knisely, Naomi Adjei, Bryan Fellman, Ying Yuan, Ami Patel +16 more

Generalized phase I‐II designs to increase long term therapeutic success rate

Pharmaceutical Statistics(2023)10.1002/pst.2301

N/A

0DataRank · unranked

12 citations

Yong Zang, Ying Yuan, Peter F. Thall

Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience

Neuro-Oncology Advances(2023)10.1093/noajnl/vdad032

N/A

0DataRank · unranked

12 citations

Max Mastall, Heather Lin, Kenneth R. Hess, Ying Yuan, Manuela Martín-Bejarano García +21 more

Novel Clinical Trial Designs with Dose Optimization to Improve Long-term Outcomes

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-2222

N/A

0DataRank · unranked

8 citations

Yong Zang, Andrew Chapple, Ying Yuan, Ruitao Lin, David Marín +2 more

Bone health in children with recurrent and chronic pancreatitis: A multi-center cross sectional analysis

Pancreatology(2023)10.1016/j.pan.2023.08.006

N/A

0DataRank · unranked

5 citations

Lindsey Hornung, Kate Ellery, Douglas S. Fishman, Tanja Gonska, Cheryl E. Gariepy +15 more

Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer

Journal of Immunotherapy and Precision Oncology(2023)10.36401/jipo-22-23

N/A

0DataRank · unranked

1 citations

Heather Lin, Siqing Fu, Amadeo B. Biter, Ecaterina E. Dumbrava, Daniel D. Karp +15 more

Disparities in dosing, drug reduction, and drug discontinuation among US FDA approved tyrosine kinase inhibitors

F1000Research(2023)10.12688/f1000research.124601.1

N/A

0DataRank · unranked

0 citations

Niamh Coleman, Clark R. Andersen, Ying Yuan, Vivek Subbiah, Neha K. Reddy

BOIN: a novel Bayesian design platform to accelerate early phase brain tumor clinical trials

Neuro-Oncology Practice(2021)10.1093/nop/npab035

N/A

0DataRank · unranked

8 citations

Jing Wu, Mark R. Gilbert, Ying Yuan

An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus

Neuro-Oncology(2021)10.1093/neuonc/noab128

N/A

0DataRank · unranked

15 citations

Shoudong Li, Joy Gumin, Marc Daou, Daniel Ledbetter, Jing Yang +8 more

Clinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience

Neuro-Oncology Advances(2021)10.1093/noajnl/vdab079

N/A

0DataRank · unranked

17 citations

Max Mastall, Heather Lin, Seyede Shiva Dibaj, Kenneth R. Hess, Ying Yuan +21 more

Novel polymer-based system for intrauterine delivery of everolimus for anti-cancer applications

Journal of Controlled Release(2021)10.1016/j.jconrel.2021.10.008

N/A

0DataRank · unranked

9 citations

Sarita R. Shah, Yunyun Jiang, Joseph Dottino, Emma Watson, Hannah A. Pearce +11 more

Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0566

N/A

0DataRank · unranked

13 citations

Zachary R. McCaw, Alex Koong, Christine Lin, Joseph Abi Jaoude, Roshal R. Patel +14 more

uTPI: A utility‐based toxicity probability interval design for phase I/II dose‐finding trials

Statistics in Medicine(2021)10.1002/sim.8922

N/A

0DataRank · unranked

24 citations

Jiguo Cao, Ying Yuan, Ruitao Lin, Haolun Shi

The Tuberculosis Drug Accelerator at year 10: what have we learned?

Nature Medicine(2021)10.1038/s41591-021-01442-2

N/A

0DataRank · unranked

62 citations

David Barros-Aguirre, Clifton E. Barry, Robert H. Bates, Steven J. Berthel, Helena I. Boshoff +32 more

ROMI: a randomized two-stage basket trial design to optimize doses for multiple indications

Biometrics(2024)10.1093/biomtc/ujae105

N/A

0DataRank · unranked

4 citations

Peter F. Thall, Kentaro Takeda, Ying Yuan, Shuqi Wang

The risk and burden of thromboembolic and hemorrhagic events in patients with malignant gliomas receiving bevacizumab

Journal of Neuro-Oncology(2024)10.1007/s11060-023-04551-9

N/A

0DataRank · unranked

7 citations

Alexander Ou, Heather Lin, Timothy A. Gregory, Kristin Alfaro-Munoz, Ying Yuan +5 more

Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer

iScience(2024)10.1016/j.isci.2024.109801

N/A

0DataRank · unranked

5 citations

Emily Hinchcliff, Elisabeth Gardiner, Reshma Rangwala, Kathryn Lito, Bryan Fellman +6 more

Bayesian estimation of semiparametric nonlinear dynamic factor analysis models using the Dirichlet process prior: Semiparametric nonlinear DFA models with the DP prior

UNC Libraries(2020)10.17615/zv24-sy66

N/A

0DataRank · unranked

0 citations

Hongtu Zhu, Song Xin-yuan, Niansheng Tang, Ying Yuan, Sy Miin Chow

Prospective, longitudinal digital activity monitoring before and after treatment of low-risk oropharyngeal squamous cell carcinoma: A feasibility study.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.6578

N/A

0DataRank · unranked

0 citations

Renata Ferrarotto, Faye M. Johnson, Diana Bell, Richard C. Cardoso, Jason M. Johnson +11 more

A Bayesian quasi-likelihood design for identifying the minimum effective dose and maximum utility dose in dose-ranging studies

Statistical Methods in Medical Research(2024)10.1177/09622802241239268

N/A

0DataRank · unranked

2 citations

Ruitao Lin, Li Wang, Ying Yuan, Feng Tian

Global Statistics and Data Sciences (GSDS), BeiGene USA, Fulton, MD

Medical Research Archives(2024)10.18103/mra.v11i11.5088

N/A

0DataRank · unranked

0 citations

Haitao Pan, Gregory H. Reaman, Satrajit Roychoudhury, Chengxing Lu, Lindsay A. Renfro +5 more

Broad-Spectrum Antimicrobial Activity and Improved Stability of a D-Amino Acid Enantiomer of DMPC-10A, the Designed Derivative of Dermaseptin Truncates

Antibiotics(2020)10.3390/antibiotics9090627

N/A

0DataRank · unranked

28 citations

Ying Yuan, Zhuming Ye, Mei Zhou, Chengbang Ma, Zhanzhong Shi +5 more

Keyboard design for phase I drug-combination trials

Contemporary Clinical Trials(2020)10.1016/j.cct.2020.105972

N/A

0DataRank · unranked

41 citations

Ruitao Lin, Yanhong Zhou, Ying Yuan, Haitao Pan

COCA: a randomized Bayesian design integrating dose optimization and component contribution assessment for combination therapies

Biometrics(2025)10.1093/biomtc/ujaf077

N/A

0DataRank · unranked

1 citations

Ruitao Lin, Ying Yuan, Xiaohan Chi

Sample-size determination for decentralized clinical trials

International Journal of Epidemiology(2025)10.1093/ije/dyaf053

N/A

0DataRank · unranked

0 citations

Ruitao Lin, Suyu Liu, Ying Yuan, Feng Tian

EphA2 siRNA in DOPC nanoliposomes (EPHARNA): A phase I clinical trial in patients with solid tumors.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.3086

N/A

0DataRank · unranked

0 citations

Aung Naing, Gabriel Lopez‐Berestein, Cristian Rodríguez-Aguayo, Hassan Ahmed Momin, Anupama Madhyannapu +11 more

Precision generalized phase I-II designs

Biometrics(2025)10.1093/biomtc/ujaf043

N/A

0DataRank · unranked

0 citations

Peter F. Thall, Ying Yuan, Juhee Lee, Pavlos Msaouel, Yong Zang +1 more

BOP2-Comb: Bayesian Optimal Phase II Design for Optimizing Doses and Assessing Contribution of Components in Drug Combinations

Therapeutic Innovation & Regulatory Science(2025)10.1007/s43441-025-00860-5

N/A

0DataRank · unranked

0 citations

Ying Yuan, Ruitao Lin, Xiaohan Chi

Characterization of Alpha-Bungarotoxin Antibodies Prepared by Different Strategies

Toxins(2025)10.3390/toxins17120601

N/A

0DataRank · unranked

0 citations

Guowen Zhang, Lin Zhao, Ying Yuan, Bing Gong, Bin Han +2 more

Health‐Related Quality of Life in Pediatric Acute Recurrent or Chronic Pancreatitis

Journal of Pediatric Gastroenterology and Nutrition(2022)10.1097/mpg.0000000000003420

N/A

0DataRank · unranked

14 citations

Fuchenchu Wang, Cheryl E. Gariepy, Gretchen A. Cress, Maisam A. Abu‐El‐Haija, Melena D. Bellin +22 more

A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma

Neuro-Oncology(2020)10.1093/neuonc/noaa062

N/A

0DataRank · unranked

46 citations

Jing Wu, Ying Yuan, Terri S. Armstrong, Elizabeth Vera, Jimin Wu +18 more

A Bayesian piecewise exponential phase II design for monitoring a time‐to‐event endpoint

Pharmaceutical Statistics(2022)10.1002/pst.2256

N/A

0DataRank · unranked

5 citations

Peter F. Thall, Ying Yuan, Yun Qing

Germline polymorphisms in MGMT associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825

Neuro-Oncology Advances(2022)10.1093/noajnl/vdac152

N/A

0DataRank · unranked

2 citations

Renke Zhou, Mark R. Gilbert, Melissa L. Bondy, Erik P. Sulman, Ying Yuan +15 more

Futility and toxicity monitoring without halting for interim analyses.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.e13579

N/A

0DataRank · unranked

0 citations

Shannon N. Westin, Ying Yuan, Diana L. Urbauer

Ying Yuan

Indexed papers

Top data-sharing exemplar

Papers